[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Society for Neurosonology and Cerebral Circulation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100492855","non-immunogenic-staphylokinase-in-reperfusion-therapy-of-ischemic-stroke-in-routine-clinical-practice-100492855",false,"NCT05697575","Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","REPIN","Inclusion Criteria:\n\n* Age 18-85 ;\n* Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;\n* Thrombolytic therapy with the drug \"non-immunogenic staphylokinase\" is planned or has already been performed.\n\nExclusion Criteria:\n\n* Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;\n* The presence of a contraindication to thrombolytic therapy of ischemic stroke;\n* Pregnancy or lactation.","ALL","18 Years","85 Years",{"count":21,"type":22},336,"ESTIMATED","1 Year","OBSERVATIONAL","The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.",[27],"Acute Stroke",[29,30,31],"stroke thrombolysis","acute ischemic stroke","reperfusion","RECRUITING","2026-04-09",{"date":35,"type":36},"2026-04-13","ACTUAL",{"date":38,"type":36},"2023-02-01",{"date":40,"type":22},"2030-05-10",{"name":42,"class":43},"National Society for Neurosonology and Cerebral Circulation","OTHER",""]